Acadia Pharmaceuticals Inc
ACAD
ISIN null / Valor 1184425
Acadia Pharmaceuticals Inc
UMushroom community rating:
About company
Acadia Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing treatments for central nervous system (CNS) disorders. With more than three decades of experience in the healthcare industry, Acadia introduced the first approved therapies targeting hallucinations and delusions in Parkinson’s disease psychosis and Rett syndrome. The company continues to advance its clinical pipeline, focusing on innovative treatments for conditions such as Prader-Willi syndrome, Alzheimer’s disease psychosis, and other neuropsychiatric symptoms associated with CNS disorders. Acadia's efforts aim to address unmet medical needs and improve the quality of life for individuals affected by these challenging conditions.
Summarized from source with an LLMView SourceSector: TechnologyKey figures
Performance
Volatility
4541 M
Market cap (USD)
1,951,217
Daily traded volume (Shares)
16.81 / 16.52
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
